Here, Steven Pavletic, MD, MS, from the National Cancer Institute, Bethesda, MD, outlines areas of improvement for treating chronic graft-versus-host disease (GvHD), the future therapeutic landscape, and encourages patient enrollment in clinical trials to help further knowledge. Dr Pavletic was speaking from the European Society for Blood and Marrow Transplantation (EBMT) 2018 Annual Meeting, held in Lisbon, Portugal.
Bringing ibrutinib to the frontline of chronic GvHD treatment
